Covid-19 takes its toll on medtechs’ efficiency

In some cases the pandemic has accelerated trends among the biggest device makers, and in others it has reversed them. A look at the medtech revenues the top 15 companies generated for the size of their workforce, a measure of the efficiency of their operations, reveals some notable fluctuations.

Even the roster of companies that make up that top 15 has changed. Zimmer Biomet and Coloplast suffered such a dramatic loss of value across 2020 that they fell out of this cohort entirely, to be replaced by the ventilator maker Resmed and the diabetes tech company Dexcom.